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Metabolic syndrome and lower urinary tract symptoms
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INTRODUCTION
A complete or partial combination of such symptoms 
as abdominal obesity, insulin resistance or type 2 
diabetes mellitus, atherogenic dyslipidemia, arterial 
hypertension, hemostatic system disorders, endothelial 
dysfunction, and chronic subclinical inflammation 
is described in the literature as metabolic syndrome 
(MS).[1]. Every year, the MS problem deserves more 
attention, as there is a significant increase in patients 
suffering from this syndrome, both in economically 
developed and developing countries.[2] The prevalence 
in the middle age groups (30–50 years) in Europe is 
19–29% and in the USA up to 39%.[3,4] Unfortunately, 
this trend is also relevant for Russia.[5] For example, 
participation in the international study “Determinants 
of cardiovascular diseases in Eastern Europe: A 
multicenter cohort study” of the Welcome Trust 
Foundation (UK), allowed for the first time to obtain 
data on the prevalence of MS in Russia according to 
the criteria of NCEP ATP III. According to the data, 
26% of Novosibirsk residents aged 45–69 years suffer 
from MS.[6]
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One of the reasons for the development of 
MS or its result but rather both is androgen 
deficiency. Deficiency of testosterone along with 
hypodynamia and nutritional factor contributes to 
the manifestation of MS. Consequently, as many 
authors have shown, correction of hypogonadism 
has a positive effect on the anthropometric and 
biochemical components of MS, as well as on the 
concentration of markers of inflammation.[7] An 
equally complex problem is the so-called chronic 
pelvic pain syndrome (CPPS). According to the 
recommendations of the European Association 
of Urologists (EAU) 2015, CPPS and prostatic 
pain syndrome occupy 90% of the structure of 
inflammatory diseases of the prostate gland. 
Currently, this pathology is considered in a variety 
of pathogenetic theories, and the search for the 
prevalent remains relevant. In our work, we tried 
to reveal the regularity of the course of CPPS, 
lower urinary tract symptoms (LUTS), and erectile 
dysfunction (ED) from the presence of MS in 
patients.
The Aim of the Study
The aim is to study the search for correlations of the 
MS with CPPS and miscarriage in men.
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MATERIALS AND METHODS
The interest of our study was a group of 16 men 
with MS at the age of 40–50 years on average 
48.5 ± 2.8 years who turned to an endocrinologist 
for overweight and did not have an established 
diagnosis of diabetes. A comparable age group of 48.6 
± 2.4 years included 13 men without MS (P < 0.05, 
Figure 1). The groups noted significant differences 
in such anthropometric parameters as weight, waist 
circumference, and body mass index, which in the 
main group were 94.1 ± 7.7 kg. 108.3 ± 10.3 cm, 
and 30.6 ± 1.3, respectively, which is greater than 
the control group: 77.9 ± 6.4 kg, 87.8 ± 4.8 cm, and 
24.4 ± 0.5 (P < 0.05, Figure 1).
Additional criteria for inclusion in the study were 
the normal level of prostate-specific antigen and the 
absence of inflammatory changes in the ejaculate. All 
patients signed informed consent.
Exclusion Criteria
Patients’ refusal to participate in the study, female 
sex, established diagnosis of “diabetes mellitus,” 
the presence of leukocytes in the analysis of urine 
after prostate massage, the presence of pathogenic 
microflora in the secretion of the prostate, and patients 
under the supervision of a neurologist were excluded 
from the study.
Patients were questioned on ASM questionnaires, 
International Prostatic Symptom Score (IPSS), pain 
scale Leeds assessment of neuropathic symptoms and 
signs (LANSS), and MIEF-5. An objective (physical) 
examination was performed. Laboratory diagnostics 
included the determination of the following 
parameters: Testosterone total and free, sex hormone-
binding globulin, luteinizing hormone, insulin, 
glucose, glycosylated hemoglobin, and lipid profile. 
All patients underwent uroflowmetry, ultrasound 
of the bladder with determination of residual urine 
volume, and prostate transrectal ultrasound, with 
measurement of blood flow.
The reliability of the differences was determined by 
the nonparametric Mann–Whitney criterion, and the 
differences were considered statistically significant 
for a probability >95%.
RESULTS AND DISCUSSION
The analysis of subjective evaluation of ED 
expression in the observation groups on the basis of 
the valid ICEF-5 scale made it possible to adequately 
and quickly assess the extent of erectile disorders. In 
doing so, we obtained the expected results, according 
to which the patients in the main group had a 
significantly lower overall score - 7.8 ± 0.9 compared 
with men not having MS - 14.3 ± 1.0 points (P <0.05, 
Figure 2). The presence of hypogonadism in the main 
group corresponds to the literature data on the MS 
problem. In our study, the level of testosterone in the 
main observation group was 10.3 ± 0.9 nmol/L and 
was significantly lower than that in the control group 
16.0 ± 1.3 nmol/L (P <0.05, Figure 2). The results 
obtained by us agree with other studies [8] which also 
confirms the hypothesis that MS is an independent 
factor of hypogonadism and ED [9,10].
In the analysis of the IPSS questionnaire, it was found 
that patients of both observation groups had a violation 
of the study. However, the studied index in patients 
with MS before the urologist’s visit had a gradation 
of severe disorders and there was significantly more 
control. However, the studied index in patients with 
MS before the urologist’s visit had a gradation of severe 
disorders and there was significantly more than control. 
Figure 1: Morphometric data in observation groups. *There 
are statistically significant differences (P < 0.05)
Figure 2: Index of erectile function on the scale of ICEF 
(5) in relation to the level of total testosterone. *There are 
statistically significant differences (P < 0.05)
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It was 24.6 ± 2.7 points against 16.9 ± 2.6 points in the 
control group. (P <0.05, Figure 3). Respondents of the 
main group mainly worried about irritative symptoms 
which led to a significant decrease in the quality of 
life (QoL) in this observation group. The average 
value of the QoL index in the main observation group 
was 4.5 ± 0.7 points, whereas in the control group, 
this figure did not exceed 3.2 ± 0.6 points (P < 0.05, 
Figure 3). The increase in the severity of LUTS could 
not be explained by the mechanical obstruction of the 
vesicourethral segment, so in the study groups, there 
were no differences in both the volume of the prostate 
and the volume of residual urine. The volume of the 
prostate gland in the main observation group was 28.4 
± 1.2 cm3 versus 24.1 ± 0.9 cm3 in the control group 
(P > 0.05, Figure 3). In patients of both observation 
groups, the volume of residual urine was not clinically 
significant. This indicator in the main group was 15.7 
± 12.1 ml in men, and in the control group, it was 7.2 
± 5.8 ml (P > 0.05, Figure 3).
Uroflowmetry also revealed no symptoms of 
bladder outlet obstruction, since the interpretation 
uroflourogram observation group registered significant 
differences in magnitude of the maximum urine flow 
(P > 0.05, Figure 4). However, in patients with MS, 
the mean space velocity of urination was lower due to 
an increase in the time of urination. The mean space 
velocity of urination in the main observation group was 
14.8 ± 2.7 ml/s, whereas in the control group, it was 
18.2 ± 3.5 ml/s (P < 0.05, Figure 4). The increasing 
time of urination, obtained in our study in patients 
with MS, we associate with repeated reductions of the 
detrusor, especially at the end of the study, which can 
be attributed to the manifestation of its hyperactivity. 
The duration of urination in the MS group was 
32.8 ± 4.2 versus the control group - 21.4 ± 3.5 seconds 
(P < 0.05, Figure 4).
The analysis of the pain scale of LANSS showed 
significant differences in the observation groups. 
Hence, in the main group prevalent pain symptoms 
were due to Orchidalia, Prostatodynia, Strangury. 
Based on the LANSS scale in the group with MS, 
the total score was 17.4 ± 0.9, while in the control, it 
was 8.2 ± 0.4 points (P < 0.05, Figure 5). A detailed 
questioning of the patients of the main observation 
group was established. That chronic pain, as a 
manifestation of CPPS, was in fact one of the main 
factors in seeking medical help. In the literature, 
there is a rather large number of publications on the 
dependence of CPPS on the degree of development 
of atherosclerosis and ischemia. To study this 
hypothesis, we evaluated blood flow in the prostate 
in patients of both observation groups. The following 
results were obtained: Peak flow velocity in the main 
group Vmax reached 13.8 ± 1.9 mm/s and in the 
Figure 3: Correlations between the severity of lower urinary 
tract symptoms and ultrasound data. *There are statistically 
significant differences (P < 0.05)
Figure 4: Urofluorogram indices in the groups in the 
observation groups. *There are statistically significant 
differences (P < 0.05)
Figure 5: Severity of the chronic pelvic pain syndrome from 
blood flow in the prostate. *There are statistically significant 
differences (P < 0.05)
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control Vmax - 14.1 ± 1.8 mm/s points (P > 0.05, 
Figure 5). The absence of significant differences was 
also demonstrated for the resistance index, which in 
the main group was 0.6 ± 0.03 ad in the control was 
0.61 ± 0.02 (P > 0.05, Figure 5).
Analyzing the data on the prevalence of the above 
pathology, one can judge about its significant increase 
in the population, which is regarded as a negative 
factor not only for a specific person but also for society 
as a whole. Currently available publications on earlier 
studies on MS do not allow obtaining a unified opinion 
about its influence on the course of many pathological 
processes. Along with the confirming results, there is 
also refuting. Focusing on our own results and literary 
data, we consider the evidence of hypogonadism and 
related ED in patients with MS. The data obtained on 
the predominance of irrational symptoms in patients 
with MS are quite interesting and, in our view, are 
related to the detrusor’s hyperactivity. This may be 
the result of systemic proinflammatory cytokinemia 
associated with MS or ischemia detrouzov due to 
a deficiency of nitric oxide, as a consequence of 
hypogonadism.[11]
CONCLUSIONS
Men who are on the border of young and middle age 
groups and who have morphometric signs of a MS 
are also at risk of having both hypogonadism and 
accompanying ED, that, however, is not the reason 
for seeking help from a urologist. Violations of 
urination in these patients consist in the predominance 
of irrational symptoms and do not correlate with the 
volume of the prostate and residual urine. In addition, 
in this group, we often recorded the presence of CPPS 
without significant changes in the blood flow in the 
prostate gland. The findings can be a manifestation of 
a systemic inflammatory reaction associated with MS.
Hence, MS acts as an independent factor of ED and 
hypogonadism, which leads to disturbances in the 
development of the brain tissue and the development 
of CPPS. It is necessary to continue research in 
this direction because understanding details of the 
pathogenesis of these complications will allow for 
adequate pathogenic therapy.
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